A5007390273- Gastrointestinal Tumor Research and Treatment
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Metastasis and carcinoma case studies
- Vascular Tumors and Angiosarcomas
- Gastrointestinal disorders and treatments
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- PI3K/AKT/mTOR signaling in cancer
- Cardiac tumors and thrombi
- CAR-T cell therapy research
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Diagnosis and Treatment
- Histiocytic Disorders and Treatments
- Synthesis and Reactivity of Sulfur-Containing Compounds
- Cutaneous Melanoma Detection and Management
- RNA modifications and cancer
- Neuroendocrine Tumor Research Advances
- Tumors and Oncological Cases
- Neurofibromatosis and Schwannoma Cases
- Cancer Genomics and Diagnostics
- Organophosphorus compounds synthesis
- Global Education Systems and Policies
- Peptidase Inhibition and Analysis
- Multiple and Secondary Primary Cancers
The Maria Sklodowska-Curie National Research Institute of Oncology
2011-2023
Narodowy Instytut Leków
2023
Medical University of Lodz
2011-2021
Sarcoma Oncology Center
2018
Centrum Onkologii
2016
Gastrointestinal stromal tumors (GIST) mutational status is recognized factor related to the results of tyrosine kinase inhibitors therapy such as imatinib (IM) or sunitinib (SU). Arterial hypertension (AH) common adverse event SU, reported predictive in renal cell carcinoma. The aim study was analyze outcomes and factors predicting SU inoperable/metastatic CD117(+) GIST patients after IM failure. We identified 137 consecutive with advanced treated one center (2nd line treatment). Median...
Alveolar soft part sarcoma (ASPS) is a rare, highly vascularized tissue characterized by high frequency of metastatic disease and resistance to classical chemotherapy. The purpose our analysis was assess long-term sunitinib activity in the treatment ASPS.Between 2009 2015, 15 patients were diagnosed with ASPS received therapy at initial continuous daily dosing 37.5 mg. Median age 32 years. primary tumor sites lower extremities (8), trunk-retroperitoneum/pelvis (2), upper extremity (3) other...
Esophageal cancer (EC) is a malignant tumor with typically poor prognosis for patients. It well known that certain microRNA (miRNA/miR) genes can regulate other responsible carcinogenesis. In the present study, group of these (miR-21, miR-134, miR-205 and miR-495) connected cancer-related pathways (MET, MMP9, PDGFA SERPINE1) were chosen analysis in order to find potential correlation between their expression clinicopathological factors EC. tumors adjacent non-cancerous tissue specimens...
Perivascular epithelioid cell tumors (PEComa) represent a family of rare mesenchymal resultant from deregulation in mTOR pathway activity. The aim this study is to evaluate the long-term efficacy targeted PEComa treatment. We reviewed all consecutive patients with who started systemic treatment sirolimus our reference sarcoma center between January 2011 and August 2020. Histopathology was confirmed cases by designated pathologist. Any surviving progression-free were censored at last...
The landscape of melanoma management changed as randomized trials have launched adjuvant treatment.An analysis data on 248 consecutive stage III and IV patients given therapy in eight centers (February 2019 to January 2021) was conducted.The analyzed cohort comprised 147 anti-PD1 (33% nivolumab, 26% pembrolizumab), 101 (41%) were dabrafenib plus trametinib (DT). 2-year overall survival (OS), relapse-free (RFS), distant-metastases-free (DMFS) rates 86.7%, 61.4%, 70.2%, respectively. disease...
was to analyze the outcome of treatment and factors predicting results sorafenib therapy in inoperable/metastatic CD117-positive GIST patients after failure on imatinib sunitinib.We identified 60 consecutive (40 men, 20 women) with advanced at least sunitinib treated one sarcoma center initial dose 2 × 400 mg daily 2007-2015 (in 56 cases it 3rd line therapy). Median follow-up time 39 months.One year progression-free survival (PFS; calculated from date start disease progression) rate 23%...
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Cybulska-Stopa B, Ługowska I, Jagodzńska-Mucha P, et al. Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study. Advances Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2019;36(5):566-571. doi:10.5114/ada.2018.79940. APA Cybulska-Stopa, B., Ługowska, I., Jagodzńska-Mucha, P., Koseła-Paterczyk, H., Kozak, K., & Klimczak, A. (2019)....
Objective: We assessed the status of BRAF V600E mutation in cell-free circulating tumor DNA (cfDNA) isolated from plasma patients with metastatic melanoma treated inhibitor vemurafenib, collected at different time points during therapy to evaluate sensitivity and specificity quantitative polymerase chain reaction droplet digital (ddPCR) correlation between level cfDNA p.V600E long-term clinical outcome. Methods: BRAF-mutated ( n = 62) was analyzed baseline 4−8 weeks start vemurafenib...
Neutrophil-to-lymphocyte ratio (NLR) was shown to be prognostic in several solid malignancies. There are limited data about predictive/prognostic value of NLR during targeted therapy patients with advanced gastrointestinal stromal tumors (GIST). The aim this study asses a clinical GIST.Between 2001 and 2016, 385 metastatic/unresectable GIST treated initially imatinib were included the analysis. In all patients, assessed at baseline, after 3 months treatment, upon disease progression (or last...
Neutrophil-to-lymphocyte ratio (NLR) has been shown to be prognostic in several solid malignancies. There are limited data regarding its value during novel therapies patients with melanoma. The aim of the study was assess practical utility this BRAF-mutant melanoma treated a combination BRAF and MEK inhibitors (BRAFi/MEKi). We included 215 inoperable or metastatic who underwent BRAFi/MEKi treatment between October 2015 June 2017. Baseline NLR other complete blood count-derived inflammatory...
Background: Recent years have brought the dynamic development of a new method cancer treatment: immunotherapy. Monoclonal antibodies blocking programmed death receptor 1 (PD-1) are now widely used in treatment several malignancies: melanoma, lung, head and neck cancer, among others. The therapeutic benefit immunotherapy soft tissue sarcoma (STS) has not yet been proven. exception is results obtained rare STS subtype alveolar part (ASPS). Case report: We describe case man with diagnosis...
The neutrophil‑to lymphocyte ratio (NLR) has been proven to be correlated with outcomes in various cancer types, including gastrointestinal stromal tumors (GIST). There is limited data regarding the clinical value of NLR during second line therapy after failure imatinib and there an urgent need for more precise predictive factors therapy. aim this study was assess association pretreatment progression free survival (PFS) overall (OS) patients unresectable/metastatic GIST treated sunitinib a...
AbstractCytotoxicities of several new aminophosphonic compounds bearing 2-furyl moiety 2b-d and 3a-c on KYSE 30, 150, 270 esophageal cancer cell lines are reported here. The qualitative study correlations between the structure cytotoxic activity furan-deriving aminophosphonates has been performed.Dimethyl (2-furyl)-N-(2-methoxyphenyl)aminomethylphosphonate (2a), which previously shown to have interesting values cytotoxicity these was tested found induce apoptosis. analyses apoptosis,...
Wstęp . Trabektedyna jest lekiem zarejestrowanym do leczenia chorych z rozpoznaniem zaawansowanych mięsakow tkanek miękkich. Badania wykazały jej skuteczność w leczeniu paliatywnym, zwłaszcza tłuszczakomięsakach (LPS — liposarcoma ) i mięśniakomięsaku gładkokomorkowym (LMS leiomyosarcoma ). Celem badania była analiza wynikow trabektedyną pacjentow leczonych jednym ośrodku. Materiały metody Od kwietnia 2008 roku października 2013 leczono 50 (23 kobiety, 27 mężczyzn) miejscowo przerzutowych...
10017 Background: The purpose of the study was to analyze outcomes treatment and factors predicting effects SU therapy in inoperable/metastatic GIST CD 117(+) patients after failure on imatinib therapy. Mutational status is well-known factor related results with tyrosine kinase inhibitors. Arterial hypertension common adverse event during but it also reported as predictive for renal-cell carcinoma patients—this last phenomenon has not been analyzed patients. Methods: We identified 107...